Different serial changes in the neointimal condition of sirolimus-eluting stents and paclitaxel-eluting stents: An optical coherence tomographic study

EuroIntervention

Volumn 10, Issue 8, 2014, Pages 924-933

  Nakamura, Daisuke ^a   Lee, Yasuharu ^a   Yoshimura, Takahiro ^a   Taniike, Masayuki ^a   Makino, Nobuhiko ^a   Kato, Hiroyasu ^a   Egami, Yasuyuki ^a   Shutta, Ryu ^a   Tanouchi, Jun ^a   Yamada, Yoshio ^a   Hara, Masahiko ^b   Sakata, Yasuhiko ^b   Hamasaki, Toshimitsu ^b   Nishino, Masami ^a  

^a OSAKA ROSAI HOSPITAL   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Coronary artery disease; Drug eluting stents; Optical coherence tomography

Indexed keywords

HEPARIN; PACLITAXEL; RAPAMYCIN; ANTINEOPLASTIC AGENT;

ACUTE CORONARY SYNDROME; AGED; ANGIOCARDIOGRAPHY; ARTERY INTIMA PROLIFERATION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY IMAGING CATHETER; DIABETES MELLITUS; DRUG ELUTING STENT; DYSLIPIDEMIA; FEMALE; HUMAN; HYPERTENSION; IMAGING SYSTEM; INTERMETHOD COMPARISON; INTRAVASCULAR ULTRASOUND; MALE; NEOINTIMA; OCCLUSION BALLOON CATHETER; OPTICAL COHERENCE TOMOGRAPHY; PERCUTANEOUS CORONARY INTERVENTION; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; SMOKING; STENT MALAPPOSITION; STENT THROMBOSIS; UNSTABLE ANGINA PECTORIS; COHORT ANALYSIS; COMPARATIVE STUDY; CORONARY BLOOD VESSEL; CORONARY RESTENOSIS; CORONARY STENOSIS; DISEASE COURSE; MIDDLE AGED; PATHOLOGY; RETROSPECTIVE STUDY;

ACUTE CORONARY SYNDROME; AGED; ANTINEOPLASTIC AGENTS; COHORT STUDIES; CORONARY RESTENOSIS; CORONARY STENOSIS; CORONARY VESSELS; DISEASE PROGRESSION; DRUG-ELUTING STENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOINTIMA; PACLITAXEL; PERCUTANEOUS CORONARY INTERVENTION; RETROSPECTIVE STUDIES; SIROLIMUS; TOMOGRAPHY, OPTICAL COHERENCE;

EID: 84920124819     PISSN: 1774024X     EISSN: 19696213     Source Type: Journal    
DOI: 10.4244/EIJV10I8A159     Document Type: Article

References (29)

1. Stettler C, Wandel S, Allemann S, Kastrati A, Morice MC, Schomig A, Pfisterer ME, Stone GW, Leon MB, de Lezo JS, Goy JJ, Park SJ, Sabate M, Suttorp MJ, Kelbaek H, Spaulding C, Menichelli M, Vermeersch P, Dirksen MT, Cervinka P, Petronio AS, Nordmann AJ, Diem P, Meier B, Zwahlen M, Reichenbach S, Trelle S, Windecker S, Juni P. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet. 2007;370:937-48.
2. Marroquin OC, Selzer F, Mulukutla SR, Williams DO, Vlachos HA, Wilensky RL, Tanguay JF, Holper EM, Abbott JD, Lee JS, Smith C, Anderson WD, Kelsey SF, Kip KE. A comparison of bare-metal and drug-eluting stents for off-label indications. N Engl J Med. 2008;358:342-52.
3. Costa MA, Simon DI. Molecular basis of restenosis and drug-eluting stents. Circulation. 2005;111:2257-73.
4. Awata M, Kotani J, Uematsu M, Morozumi T, Watanabe T, Onishi T, Iida O, Sera F, Nanto S, Hori M, Nagata S. Serial angioscopic evidence of incomplete neointimal coverage after sirolimus-eluting stent implantation: comparison with bare-metal stents. Circulation. 2007;116:910-6.
5. Park KW, Kim CH, Lee HY, Kang HJ, Koo BK, Oh BH, Park YB, Kim HS. Does "late catchup" exist in drug-eluting stents: insights from a serial quantitative coronary angiography analysis of sirolimus versus paclitaxel-eluting stents. Am Heart J. 2010;159:446-53.
6. Gutierrez-Chico JL, van Geuns RJ, Regar E, van der Giessen WJ, Kelbaek H, Saunamaki K, Escaned J, Gonzalo N, di Mario C, Borgia F, Nuesch E, Garcia-Garcia HM, Silber S, Windecker S, Serruys PW. Tissue coverage of a hydrophilic polymer-coated zotarolimus-eluting stent vs. a fluoropolymer-coated everolimus-eluting stent at 13-month follow-up: an optical coherence tomography substudy from the RESOLUTE All Comers trial. Eur Heart J. 2011;32:2454-63.
7. Finn AV, Joner M, Nakazawa G, Kolodgie F, Newell J, John MC, Gold HK, Virmani R. Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation. 2007;115:2435-41.
8. Teramoto T, Ikeno F, Otake H, Lyons JK, van Beusekom HM, Fearon WF, Yeung AC. Intriguing peri-strut low-intensity area detected by optical coherence tomography after coronary stent deployment. Circ J. 2010;74:1257-9.
9. Lin LK. A concordance correlation coefficient to evaluate reproducibility. Biometrics. 1989;45:255-68.
10. Kim JS, Kim TH, Fan C, Lee JM, Kim W, Ko YG, Choi D, Hong MK, Jang Y. Comparison of neointimal coverage of sirolimus-eluting stents and paclitaxel-eluting stents using optical coherence tomography at 9 months after implantation. Circ J. 2010;74:320-6.
11. Buch AN, Waksman R. Cypher versus Taxus: all smoke and no fire: lessons for future comparative drug-eluting stent trials in interventional cardiology. Am J Cardiol. 2007;99:424-7.
12. Cook S, Wenaweser P, Togni M, Billinger M, Morger C, Seiler C, Vogel R, Hess O, Meier B, Windecker S. Incomplete stent apposition and very late stent thrombosis after drug-eluting stent implantation. Circulation. 2007;115:2426-34.
13. Räber L, Baumgartner S, Garcia-Garcia HM, Kalesan B, Justiz J, Pilgrim T, Moschovitis A. Long-term vascular healing in response to sirolimus and paclitaxel-eluting stents: an optical coherence tomography study. JACC Cardiovasc Interv. 2012;5:946-57.
14. Morice MC, Colombo A, Meier B, Serruys P, Tamburino C, Guagliumi G, Sousa E, Stoll HP. Sirolimus vs. paclitaxel-eluting stents in de novo coronary artery lesions: the REALITY trial: a randomized controlled trial. JAMA. 2006;295:895-904.
15. Rittersma SZ, de Winter RJ, Koch KT, Bax M, Schotborgh CE, Mulder KJ, Tijssen JG, Piek JJ. Impact of strut thickness on late luminal loss after coronary artery stent placement. Am J Cardiol. 2004;93:477-80.
16. Daemen J, Tanimoto S, Garcia-Garcia HM, Kukreja N, van de Sande M, Sianos G, de Jaegere PP, van Domburg RT, Serruys PW. Comparison of three-year clinical outcome of sirolimus- and paclitaxel-eluting stents versus bare metal stents in patients with ST-segment elevation myocardial infarction (from the RESEARCH and T-SEARCH Registries). Am J Cardiol. 2007;99:1027-32.
17. Kimura T, Yokoi H, Nakagawa Y, Tamura T, Kaburagi S, Sawada Y, Sato Y, Hamasaki N, Nosaka H, Nobuyoshi M. Three-year follow-up after implantation of metallic coronary-artery stents. N Engl J Med. 1996;334:561-6.
18. Aoki J, Colombo A, Dudek D, Banning AP, Drzewiecki J, Zmudka K, Schiele F, Russell ME, Koglin J, Serruys PW. Peristent remodeling and neointimal suppression 2 years after polymerbased, paclitaxel-eluting stent implantation: insights from serial intravascular ultrasound analysis in the TAXUS II study. Circulation. 2005;112:3876-83.
19. Asakura M, Ueda Y, Nanto S, Hirayama A, Adachi T, Kitakaze M, Hori M, Kodama K. Remodeling of in-stent neointima, which became thinner and transparent over 3 years: serial angiographic and angioscopic follow-up. Circulation. 1998;97:2003-6.
20. Degertekin M, Serruys PW, Foley DP, Tanabe K, Regar E, Vos J, Smits PC, van der Giessen WJ, van den Brand M, de Feyter P, Popma JJ. Persistent inhibition of neointimal hyperplasia after sirolimus-eluting stent implantation: long-term (up to 2 years) clinical, angiographic, and intravascular ultrasound follow-up. Circulation. 2002;106:1610-3.
21. Katoh H, Shite J, Shinke T, Matsumoto D, Tanino Y, Ogasawara D, Sawada T, Miyoshi N, Kawamori H, Yoshino N, Hirata K. Delayed neointimalization on sirolimus-eluting stents: 6-month and 12-month follow up by optical coherence tomography. Circ J. 2009;73:1033-7.
22. Tsuchida K, Serruys PW, Bruining N, Dudek D, Drzewiecki J, Banning AP, Zmudka K, Schiele F, Zhou Z, Rademaker TA, van Es GA, Koglin J, Russell ME, Colombo A. Two-year serial coronary angiographic and intravascular ultrasound analysis of in-stent angiographic late lumen loss and ultrasonic neointimal volume from the TAXUS II trial. Am J Cardiol. 2007;99:607-15.
23. Hara M, Nishino M, Taniike M, Makino N, Kato H, Egami Y, Shutta R, Tanouchi J, Yamada Y. Serial angioscopic evaluation of neointimal coverage and incidence of thrombus formation after Paclitaxel-eluting stent implantation: comparison between 6 and 18month follow-up. Clin Cardiol. 2011;34:322-6.
24. Nakazawa G, Finn AV, Vorpahl M, Ladich ER, Kolodgie FD, Virmani R. Coronary responses and differential mechanisms of late stent thrombosis attributed to first-generation sirolimus and paclitaxel-eluting stents. J Am Coll Cardiol. 2011;57:390-8.
25. Hara M, Nishino M, Taniike M, Makino N, Kato H, Egami Y, Shutta R, Yamaguchi H, Tanouchi J, Yamada Y. High incidence of thrombus formation at 18 months after paclitaxel-eluting stent implantation: angioscopic comparison with sirolimus-eluting stent. Am Heart J. 2010;159:905-10.
26. Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, Kutys R, Skorija K, Gold HK, Virmani R. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol. 2006;48:193-202.
27. Nagai H, IshibashiUeda H, Fujii K. Histology of highly echolucent regions in optical coherence tomography images from two patients with sirolimus-eluting stent restenosis. Catheter Cardiovasc Interv. 2010;75:961-3.
28. Inoue T, Shite J, Yoon J, Shinke T, Otake H, Sawada T, Kawamori H, Katoh H, Miyoshi N, Yoshino N, Kozuki A, Hariki H, Hirata K. Optical coherence evaluation of everolimus-eluting stents 8 months after implantation. Heart. 2011;97:1379-84.
29. Wang TH, Wang HS, Soong YK. Paclitaxel-induced cell death: where the cell cycle and apoptosis come together. Cancer. 2000;88:2619-28.